Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Il22 immunoconjugates

a technology of immunoconjugation and interleukin22, which is applied in the field of conjugate comprising interleukin22 and an antibody molecule, can solve the problems of not all immunocytokines retain, the preparation of immunocytokines with therapeutic effects, such as anti-inflammatory activity, is not straightforward, and the effect of increasing activity

Inactive Publication Date: 2017-10-26
PHILOGEN SRL LLC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new method to create a conjugate of interleukin-22 (IL-22) and an antibody molecule that targets a specific antigen associated with angiogenesis (the process of creating new blood vessels). The researchers found that fusing IL-22 to the N-terminus of the antibody molecule resulted in a more active conjugate compared to a conjugate created by fusing IL-22 to the C-terminus. This discovery has led to the creation of a new therapeutic agent that can be used to treat angiogenesis-related diseases, such as autoimmune diseases and inflammation. The patent also covers the use of the conjugate in methods for treating patients and delivering IL-22 to disease sites.

Problems solved by technology

Many cytokines have been used for therapeutic purposes in patients, such as those with advanced cancer, but their administration is typically associated with severe toxicity, hampering dose escalation to therapeutically active regimens and their development as anticancer drugs, for example.
However, not all immunocytokines retain, for example, the in vivo targeting properties of the parental antibody (Pasche & Neri, 2012) or expected activities.
The preparation of immunocytokines with therapeutic effects, such as anti-inflammatory activity, is therefore far from straightforward.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Il22 immunoconjugates
  • Il22 immunoconjugates
  • Il22 immunoconjugates

Examples

Experimental program
Comparison scheme
Effect test

examples

Materials and Methods

[0121]Cloning of Fusion Proteins Comprising IL22 and Anti-ED-A antibody F8

[0122]The genes encoding the antibody fusion proteins comprising muIL22 (from mus musculus) or human IL22 and anti-ED-A antibody F8 were generated using PCR assembly. The sequence encoding IL22 (lacking the signal peptide sequence) was linked via a sequence encoding a 15 amino acid glycine-serine-linker [(G4S)3] either to the C-terminus (F8-IL22) or the N-terminus (IL22-F8) of the gene encoding the F8 antibody in diabody format (heavy chain and light connected via a GGSGG-linker). A sequence encoding an IgG-derived signal peptide was added at the N-terminus to enable high yield production of the encoded fusion proteins.

[0123]The genes encoding the antibody fusion proteins comprising muIL22, were cloned into the pcDNA 3.1 mammalian cell expression vector using engineered NheI and NotI restriction sites. The genes encoding the antibody fusion proteins comprising huIL22 were generated by PCR ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease / disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).

Description

FIELD OF THE INVENTION[0001]The present invention relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the present invention relates to the therapeutic use of such conjugates in the treatment of a disease / disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).BACKGROUND TO THE INVENTION[0002]Cytokines are key mediators of innate and adaptive immunity. Many cytokines have been used for therapeutic purposes in patients, such as those with advanced cancer, but their administration is typically associated with severe toxicity, hampering dose escalation to therapeutically active regimens and their development as anticancer drugs, for example. To overcome these problems, the use of Immunocytokines' (i.e. cytokines fused to antibodies or antibody fragments) has been proposed, with the aim to concentra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/54C07K16/30C07K16/18A61K38/00A61K39/00
CPCC07K14/54C07K16/18C07K16/30C07K2317/622A61K2039/505C07K2317/565C07K2317/56C07K2319/70A61K38/00C07K2317/626A61K38/20C07K2319/33A61K47/6813A61K47/6849A61K47/6851A61P1/04A61P17/06A61P19/02A61P25/00A61P29/00A61P37/02A61P9/10A61P3/10C07K19/00
Inventor BOOTZ, FRANZISKA SOPHIENERI, DARIO
Owner PHILOGEN SRL LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com